Winning formulas for the best biotech and drug names

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce. This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, whi…

[Sponsored] What does the future of specialist distribution look like?

Jeff Beck of BioCare is in the hotseat for this edition of The Top Line. Beck is the Chief Development Officer at the company, which stands tall as a pioneer in specialty product distribution with over 40 years of experience dating back to hemophilia therapies. During the conversation, Beck provi…

Deep dive: Biopharma layoffs in Q1

This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024.  Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rou…

The unrecognized threat of PAD

This week on “The Top Line,” we explore peripheral arterial disease, a serious health issue that is often overlooked and undermanaged.   Join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of the Peripheral Vascular Interve…

The top money raisers in biotech

This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questi…

A closer look at European biotech investment in 2024

This week on “The Top Line,” we explore the European biotech investment landscape.  Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector.  To learn more about the t…

Inclusivity in psoriasis trials with Takeda

This week on “The Top Line,” we’re diving into the topic of diversity in clinical trials, examining both the progress made and the ongoing work needed to ensure inclusivity.  In this episode, Fierce Biotech Senior Editor Annalee Armstrong engages in a conversation with Karen Correa, Ph.D., Head of…

Fierce Medtech's Fierce 15

In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15.  To learn more about the topics in this episode:  Fierce Medtech's Fierce 15 of …

[Sponsored] A Person-Centered Approach to Achieving Long-Term Success

This week on “The Top Line,” we’re speaking with Jared Baeten, MD, Ph.D., Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment research have enabled individuals to lead longer and healthier lives by taking and staying on medication. Nevertheless, HIV per…

CAR-T boxed warnings: What comes next?

The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials.  In today’s episo…